GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Interest Income

Kyverna Therapeutics (Kyverna Therapeutics) Interest Income : $3.52 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Kyverna Therapeutics's interest income for the three months ended in Mar. 2024 was $2.74 Mil. Its interest income for the trailing twelve months (TTM) ended in Mar. 2024 was $3.52 Mil.


Kyverna Therapeutics Interest Income Historical Data

The historical data trend for Kyverna Therapeutics's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Interest Income Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Interest Income
- 0.57 2.28

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Interest Income Get a 7-Day Free Trial 0.30 0.35 - 0.79 2.74

Kyverna Therapeutics Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines